Your browser doesn't support javascript.
Progress on cross-species infection mechanism of 2019-nCoV and antiviral drug research.
Chinese Journal of Clinical Infectious Diseases ; 13(4):305-314, 2020.
Article in Chinese | EMBASE | ID: covidwho-2270124
ABSTRACT
2019-nCoV has a up to 96% homology with the gene sequence of a bat coronavirus. By comparing its 7 conserved non-structural proteins, it is found that 2019-nCoV belongs to SARS related coronaviruses(SARSr-CoV). The receptor for 2019-nCoV entering cells is the same as that for SARSr-CoV, and angiotensin-converting enzyme 2 (ACE2) is a common cross-genus receptor. This article first elaborates the interspecies transmission and genetic variation, then briefly discusses the receptors on the surface of human cells (such as ACE2 and APP4), which cause human infection and encode five proteins in the viral genome, therefore are important targets for development of antiviral drugs. The article reviews eight promising anti-coronavirus drugs, including three anti-HIV drugs (Lopinavir/Ritonavir, Danoprevir/Ritonavir, Darunavir), two anti-Ebola virus drugs (Remdesivir, Galidesivir), two anti-influenza virus drugs (Arbidol, Favipiravir) and one anti-malarial drug (chloroquine phosphate). Among them, Remdesivir, Abidol and Favipiravir have strong inhibitory effects on 2019-nCoV, they may be the most promising drugs under investigation.Copyright © 2020 by the Chinese Medical Association.
Keywords

Full text: Available Collection: Databases of international organizations Database: EMBASE Type of study: Randomized controlled trials Language: Chinese Journal: Chinese Journal of Clinical Infectious Diseases Year: 2020 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: Databases of international organizations Database: EMBASE Type of study: Randomized controlled trials Language: Chinese Journal: Chinese Journal of Clinical Infectious Diseases Year: 2020 Document Type: Article